KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Asset Writedowns and Impairment (2016 - 2025)

Emergent BioSolutions' Asset Writedowns and Impairment history spans 11 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $12.2 million; the TTM value through Dec 2025 reached $12.2 million, down 55.15%, while the annual FY2025 figure was $12.2 million, 55.15% down from the prior year.
  • Asset Writedowns and Impairment reached $12.2 million in Q4 2025 per EBS's latest filing, down from $27.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $306.7 million in Q2 2023 to a low of $12.2 million in Q4 2025.
  • Average Asset Writedowns and Impairment over 3 years is $115.4 million, with a median of $27.2 million recorded in 2024.
  • The largest YoY upside for Asset Writedowns and Impairment was 91.13% in 2024 against a maximum downside of 91.13% in 2024.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $306.7 million in 2023, then tumbled by 91.13% to $27.2 million in 2024, then tumbled by 55.15% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Asset Writedowns and Impairment are $12.2 million (Q4 2025), $27.2 million (Q2 2024), and $306.7 million (Q2 2023).